CytRx (OTCMKTS: CYTR) is one of 125 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare CytRx to similar companies based on the strength of its valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.
This is a summary of current ratings and price targets for CytRx and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares CytRx and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|CytRx Competitors||$811.27 million||$168.09 million||6.23|
CytRx’s rivals have higher revenue and earnings than CytRx. CytRx is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares CytRx and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
CytRx has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, CytRx’s rivals have a beta of 1.68, meaning that their average stock price is 68% more volatile than the S&P 500.
Institutional & Insider Ownership
7.9% of CytRx shares are held by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 6.9% of CytRx shares are held by insiders. Comparatively, 17.4% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
CytRx rivals beat CytRx on 7 of the 13 factors compared.
CytRx Company Profile
CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides albumin companion diagnostic for cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.